MedWatch

Novo Nordisk diabetes drug hit by supply issues

Supply issues are spreading at the Danish pharmaceutical firm, and Novo Nordisk’s diabetes business has now been affected.

Photo: Mads Claus Rasmussen//

Novo Nordisk has already had issues providing a sufficient supply of obesity drug Wegovy, and now diabetes drug Ozempic is joining the list of shortages, Danish business daily Børsen reports.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Bank believes in cancer approval for Genmab

In Jyske Bank’s eyes, Genmab’s newest cancer candidate is almost certain to be approved, though the bank says stock increases in the past year have reduced the upside potential for the Danish biotech firm.

Further reading

Related articles

Latest news

See all jobs